Evidence map›Paper›PMID 35760058›Full record

ArticleOncology2022

Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.

Marie Mikuteit, Stefanie Zschäbitz, Maximilian Erlmeier, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Sandra Steffens, Franziska Erlmeier

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Marie MikuteitDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Stefanie ZschäbitzDepartment of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Maximilian ErlmeierDepartment of Urology, München Klinik Bogenhausen, Munich, Germany.
Michael AutenriethDepartment of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
Wilko WeichertInstitute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
Arndt HartmannInstitute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Sandra SteffensDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Franziska ErlmeierInstitute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Medizinische Hochschule Hannover · DEUniversitätsklinikum Erlangen · DEGerman Cancer Research Center · DEHeidelberg University · DEMünchen Klinik Bogenhausen · DETUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOverexpression of tumor-associated growth arrest-specific protein 6 (Gas6) is found in many tumor entities. The prognostic value of Gas6 in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear.

aimThe aim of the study was to evaluate the prognostic impact of Gas6 expression in a large cohort of patients with chromophobe RCC (chRCC). MATERIAL AND

methodsPatients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Gas6 expression by immunohistochemistry.

resultsEighty-one chRCC patients were eligible for analysis; of these, 24 (29.6%) patients were positive for Gas6. No significant associations were found for Gas6 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Gas6- compared to Gas6+ (89.6% vs. 100.0%; p = 0.288) tumors.

conclusionIn chRCC, Gas6 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.

Indexed as

Carcinoma, Renal CellIntercellular Signaling Peptides and ProteinsKidney NeoplasmsGrowth Arrest-Specific Protein 6HumansImmunohistochemistryPrognosisRetrospective StudiesGrowth Arrest-Specific Protein 6Intercellular Signaling Peptides and ProteinsChromophobe histologyGrowth arrest-specific protein 6Renal cell carcinomaSurvival

Identifiers

PMID35760058
PMCPMC9677856
OpenAlexW4283690156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.